Biohaven (BHVN)

• Market cap: $1.59B
• 1 day: 21.59%
• 5 days: 14.71%
• 1 month: 10.56%
• 3 months: -29.48%
• 6 months: -60.00%
• Year to date: -58.15%
• 1 year: -59.41%
• 5 years: 118.49%
• 10 years: 118.49%
• Sector: Healthcare
• Industry: Biotechnology

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

304% more call options, than puts

Call options by funds: $30.7M | Put options by funds: $7.59M

27% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 37

24% more repeat investments, than reductions

Existing positions increased: 94 | Existing positions reduced: 76

3% more funds holding

Funds holding: 253 [Q4 2024] → 260 (+7) [Q1 2025]

3.45% less ownership

Funds ownership: 91.26% [Q4 2024] → 87.81% (-3.45%) [Q1 2025]

22% less funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]

37% less capital invested

Capital invested by funds: $3.48B [Q4 2024] → $2.2B (-$1.28B) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 35% upside
• Avg. target: $38 144% upside
• High target: $55 253% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

JP Morgan Tessa Romero	253% upside $55	Overweight Maintained	18 Jun 2025
RBC Capital Leonid Timashev	35% upside $21	Sector Perform Downgraded	19 May 2025